MIR143 (MicroRNA 143)

In contrast, the expression of miR-1225-3p, miR-661, and miR-143-5p showed a notable decline in pre-therapy tumors in comparison to normal tissues; however, these expressions elevated significantly in post-NAT tumor group compared to pre-therapy tumor group. Associated regulatory networks were constructed to explore candidate biomarkers that may respond to NAT treatment in BC.

We conclude that miR143 and 124 might prove as useful biomarkers to differentiate between WT and Nb; however, more comprehensive evaluation is required for confirmation of the same.

The integration of molecular profiling is refining the understanding of GT biology and expanding its therapeutic landscape. Moving beyond traditional surgery, the identification of targetable genetic alterations paves the way for personalized medicine approaches. Future efforts should focus on validating biomarkers in clinical trials to establish effective targeted therapies, ultimately improving outcomes for patients with complex or advanced GTs.

Multivariate Cox regression showed that a model of downregulated miR-16-5p and upregulated miR-451a was significantly associated with poorer survival (p = 0.023). This study indicates the future potential of exomiRs as diagnostic and prognostic liquid biopsy markers for vulvar cancer.

Since the administration of targeted treatments can result in an immune-related adverse effect, growing interest has focused on exosomes as alternative carriers for miRNA-based therapeutics. Overall, applications of miRNAs have the potential to improve CRC outcomes.

Clinical trials of Claudin 18.2-targeted therapies (e.g., Zolbetuximab) further expand personalized treatment options...Despite the abundance of research in this field, this paper prioritizes the analysis and discussion of prospective or high-quality retrospective studies that include explicit efficacy prediction endpoints (such as pCR, TRG, AUC) to ensure the reliability of the evidence presented. This review emphasizes that multi-omics integrated predictive models and the clinical translation of targeted therapies represent critical directions for future research, aiming to optimize the neoadjuvant treatment strategies for locally advanced gastric cancer.

Doxorubicin (Dox) is a widely employed chemotherapeutic agent, but its use is clinically limited by dose-accumulative cardiotoxicity...Notably, this cardioprotection is achieved without either compromising Dox's anti-tumor efficacy or producing overall toxicity. These findings establish cmSMRTs 143-122 as a minimally invasive, cardiac-selective mRNA therapy platform with strong potential to prevent chemotherapy-induced cardiotoxicity.

Collectively, these findings position TUBA1C as a central integrator of cytoskeletal organisation and oncogenic signalling. Recognising TUBA1C as a pan-cancer driver highlights its potential as a prognostic biomarker and therapeutic target, with implications for disrupting oncogenic circuits and improving precision oncology strategies.

Promising technologies help in the concise proofreading of epigenetic marks, and advanced single-cell analysis is paving the way for personalized treatment approaches. This cutting-edge knowledge of epigenetic regulation mechanisms offers new prospects for enhancing diagnosis, prognosis, and targeted therapies in colorectal cancer.

Background: HER2-positive breast cancer patients receiving chemotherapy and targeted therapy (including anthracyclines and trastuzumab) face an elevated risk of cardiotoxicity, which can lead to long-term cardiovascular complications... Circulating miRNAs show promise as biomarkers for predicting cardiotoxicity in breast cancer patients. Machine learning approaches may enhance miRNA-based risk stratification, enabling personalized monitoring and early cardioprotective interventions.

Our NGS-based analysis revealed a distinct miRNA expression signature that differentiates prostate cancer from BPH. The downregulation of several tumor-suppressive miRNAs (with concomitant upregulation of oncogenic miRNAs) in prostate cancer may contribute to malignancy-including the de-repression of novel targets like VAPB, which we identify as a promising new biomarker and therapeutic target.

We identified several miR polymorphisms and distinct haplotypes associated with reduced PCa risk in a sample of the Iranian population. These findings pave the way for optimized PCa management and provide a better understanding of its pathophysiology.